BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-128@catalystbrief.girapphe.com
DTSTAMP:20261117T181558Z
LAST-MODIFIED:20261117T181558Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Readout: Karyopharm Therapeutics Inc — Selinexor (combination the
 rapy) [Dec 2026]
DESCRIPTION:Phase 3 primary completion: A Study of Rituximab-Gemcitabine-De
 xamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Re
 lapsed/Refractory Diffuse Large B-cell Lymphoma.\nSource: https://clinical
 trials.gov/study/NCT04442022\nhttps://catalystbrief.girapphe.com/e/128?lan
 g=en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/128?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
